ProCE Banner Activity

Managing Diarrhea and Interstitial Lung Disease With Newer HER2-Directed Therapies

Clinical Thought

Rita Nanda, MD, discusses tucatinib-associated diarrhea and interstitial lung disease with trastuzumab deruxtecan treatment and offers clinical pearls for their management.

Released: December 02, 2022

Expiration: December 01, 2023

Share

Provided by

ProCE Banner

Supporters

This activity is supported by

Seagen

Faculty Disclosure

Rita Nanda, MD: researcher: Arvinas, AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Immunomedics/Gilead, Merck, OBI Pharma, Odonate, OncoSec, Pfizer, Seattle Genetics, Taiho; advisor: AstraZeneca, BeyondSpring, Fuji Film, GE, Gilead, Infinity, iTeos, Merck, OBI Pharma, OncoSec, Sanofi, Seattle Genetics.